Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367962 · ClinicalTrials.gov registry record · Phase 1
Detection of Graft Versus Host Disease With [18F]F-AraG
A Phase 1 study, sponsored by CellSight Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03367962 is a Phase 1 study that has completed, run by CellSight Technologies. The registered enrollment target is 9 participants.
The verdict
NCT03367962, a Phase 1 study, has completed, sponsored by CellSight Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of \[18F\]F-AraG.
Interventions
- DRUG [18F]F-Ara-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2023-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03367962
The ClinicalTrials.gov registry entry for NCT03367962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CellSight Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]F-Ara-G is the first listed.
NCT03367962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03367962 about?
NCT03367962 is a clinical study titled "Detection of Graft Versus Host Disease With [18F]F-AraG". This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PE...
What is the current status of trial NCT03367962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-05-15. Estimated completion is 2023-10-21.
What interventions are being tested in trial NCT03367962?
The interventions under investigation include: [18F]F-Ara-G (DRUG).
Who is sponsoring clinical trial NCT03367962?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.